Alzforum: What We Know, What We Don't Know


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		Antibodies
		Mutations
		AlzGene
		Research Models
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences
	Expert Opinion
		Ask the Expert


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Research: Forums: Live Discussions

What We Know, What We Don't Know

back to table

	What we know	What we don’t know
13.	Most but not all eFAD mutations appear to increase Abeta42, or to increase the ratio of Abeta42 to Abeta40	Do eFAD mutations cause AD through a gain of toxic function, or by the loss of an important normal function? Are there Abeta-independent effects of eFAD mutations?

Submit a Comment

Cast your vote and/or make a comment on this page.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password
*Confirm Password
Remember my Login and Password?

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.




			Print this page Email this page Alzforum News Text size Share & Bookmark Del.icio.us Digg Facebook Google Newsvine








			For the purpose of designing intervention trials for people with FAD mutation, is a presymptomatic individual a:

				Healthy person? (Drug trial risk tolerance: zero)

				Ill person? (Risk tolerance: medium)

				Person with fatal disease? (Risk tolerance: high, just check cancer.)








			Archived Polls







			Antibodies Cell Lines Collaborators Papers Research Participants